Focus: Cumberland Pharmaceuticals is a small-molecule specialty pharma company headquartered in Nashville, TN focused on niche therapeutic areas including neurology. The company maintains a portfolio of marketed products and mid-stage pipeline programs with significant revenue concentration in a single asset.
Profile data last refreshed 6h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Cumberland Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Cumberland Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Company's dominant revenue driver at 90% of total revenue; flagship asset facing patent cliff risk despite significant market position.
Help build intelligence for Cumberland Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Second-largest revenue contributor with defined LOE date of January 2027, representing concentrated near-term patent cliff exposure.
ANDA product in pre-launch phase; generic antihistamine entry indicating portfolio diversification into OTC-adjacent markets.
Niche intravenous vasopressin antagonist with limited revenue visibility; product currently experiencing supply shortages per FDA.
Formulation variant of VAPRISOL; currently on FDA shortage list as unavailable.
Combination antibiotic therapy product with approaching exclusivity cliff; limited commercial revenue disclosure.
Intravenous NSAID in peak commercial phase with extended LOE protection through 2032; key asset supporting pipeline diversification strategy.
ANDA product in post-LOE phase; represents mature generic asset with limited differentiation and margin pressure.
Critical care/emergency medicine product in peak phase with LOE protection through 2032; represents specialty niche positioning.
4 discontinued, 1 duplicate formulations not shown
No open positions listed yet.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub
Conivaptan hydrochloride injection shortage (unavailable status) represents operational risk and potential supply chain instability affecting marketed product revenue.